- Home
- ORIC vs MDXG Comparison
ORIC vs MDXG Comparison
Compare ORIC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- MDXG
- Stock Information
- Founded
- ORIC 2014
- MDXG 2006
- Country
- ORIC United States
- MDXG United States
- Employees
- ORIC N/A
- MDXG N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- MDXG Health Care
- Exchange
- ORIC Nasdaq
- MDXG Nasdaq
- Market Cap
- ORIC 940.8M
- MDXG 877.4M
- IPO Year
- ORIC 2020
- MDXG N/A
- Fundamental
- Price
- ORIC $10.12
- MDXG $7.16
- Analyst Decision
- ORIC Strong Buy
- MDXG Strong Buy
- Analyst Count
- ORIC 9
- MDXG 2
- Target Price
- ORIC $18.29
- MDXG $12.00
- AVG Volume (30 Days)
- ORIC 1.2M
- MDXG 1.1M
- Earning Date
- ORIC 08-11-2025
- MDXG 07-30-2025
- Dividend Yield
- ORIC N/A
- MDXG N/A
- EPS Growth
- ORIC N/A
- MDXG N/A
- EPS
- ORIC N/A
- MDXG 0.21
- Revenue
- ORIC N/A
- MDXG $363,774,000.00
- Revenue This Year
- ORIC N/A
- MDXG $9.55
- Revenue Next Year
- ORIC N/A
- MDXG $11.43
- P/E Ratio
- ORIC N/A
- MDXG $34.11
- Revenue Growth
- ORIC N/A
- MDXG 6.85
- 52 Week Low
- ORIC $3.90
- MDXG $5.47
- 52 Week High
- ORIC $14.67
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- ORIC 43.96
- MDXG 61.08
- Support Level
- ORIC $10.00
- MDXG $6.47
- Resistance Level
- ORIC $11.62
- MDXG $7.99
- Average True Range (ATR)
- ORIC 0.63
- MDXG 0.37
- MACD
- ORIC -0.24
- MDXG 0.04
- Stochastic Oscillator
- ORIC 20.68
- MDXG 58.29
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.